<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699179</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-3557</org_study_id>
    <nct_id>NCT00699179</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes</brief_title>
  <acronym>EFFECTIVE</acronym>
  <official_title>EFFicacious glycaEmia Control, Treatment Goal achIevement Very simplE With NovoMix 30: A Single-country, Multicentre, Prospective, Open Label, Non-controlled, Observational, 26-week Study in Serbian Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Diabetes Mellitus in Everyday Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. This observational study is aimed to reflect the
      post-authorisation experience with insulin analogue (biphasic insulin aspart 30) when used
      under normal clinical practice conditions in Serbia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline</measure>
    <time_frame>After 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving HbA1c below 7,5% for Type 1 Diabetes Mellitus, below 7.0% and below or equal to 6.5% for Type 2 Diabetes Mellitus</measure>
    <time_frame>after 12 weeks and 26 weeks compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG (glucose variability)</measure>
    <time_frame>after 12 weeks and 26 weeks compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PPG (postprandial control)</measure>
    <time_frame>after 12 weeks and 26 weeks compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin dose and number of injections</measure>
    <time_frame>at 12 weeks and 26 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oral antidiabetic drug therapy dosage and eventual discontinuation of oral antidiabetic drug therapy during the study</measure>
    <time_frame>after 12 weeks and 26 weeks of treatment compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight and waist circumference</measure>
    <time_frame>at 12 weeks and 26 weeks of treatment compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of major hypoglycaemic events during 4 weeks proceeding routine visits</measure>
    <time_frame>at 12 weeks and 26 weeks of treatment compared to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reactions (ADR)</measure>
    <time_frame>after 12 weeks and 26 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2308</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>NovoMix® 30</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 1 and 2 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or Type 2 Diabetes Mellitus inadequately controlled on human insulin therapy
             lasting for at least 6 months

          -  HbA1c greater than 7%

          -  Informed Consent

        Exclusion Criteria:

          -  Patients with a hypersensitivity to biphasic insulin aspart 30 or to any of the
             excipients

          -  Other limiting conditions specified in the locally approved NovoMix 30 SPC ( Summary
             of Product Characteristics), PIL ( Patient Information Leaflet).

          -  Women who are pregnant, breast feeding or have the intention of becoming pregnant
             within next couple of months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11 070</zip>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Former Serbia and Montenegro</country>
  </location_countries>
  <removed_countries>
    <country>Serbia</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

